1750. Deputy Albert Dolan asked the Minister for Health the status of the HSE and Department of Health assessment of Omaveloxolone (Skyclarys) for the treatment of Friedreich’s Ataxia; the timeline for completing the reimbursement process; the engagement that has taken place with patient representatives and clinical experts; and if she will make a statement on the matter. [18744/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
1751. Deputy Albert Dolan asked the Minister for Health the specific steps the HSE is taking to ensure that the time-critical nature of Friedreich’s Ataxia is fully recognised and reflected in the ongoing price negotiations for the reimbursement of Skyclarys; and if she will make a statement on the matter. [18745/26]
1752. Deputy Albert Dolan asked the Minister for Health the way in which the commitments set out in the National Rare Disease Strategy 2025–2030, particularly regarding timely access to approved therapies for rare disease patients, are being applied to the current reimbursement process for Skyclarys for the treatment of Friedreich’s Ataxia; and if she will make a statement on the matter. [18746/26]
1753. Deputy Albert Dolan asked the Minister for Health the way in which the 180-day decision timeline contained within the 2026 IPHA Framework Agreement is being implemented in the case of Skyclarys, given that over 570 days have now elapsed since the reimbursement application was submitted; and if she will make a statement on the matter. [18747/26]
1758. Deputy Louis O'Hara asked the Minister for Health if the drug Skyclarys (omaveloxolone), used for the treatment of Friedreich’s ataxia, will be made available under licence in Ireland; and if she will make a statement on the matter. [18769/26]
1759. Deputy Louis O'Hara asked the Minister for Health the specific steps that are being taken to ensure the HSE recognises the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [18770/26]
1760. Deputy Louis O'Hara asked the Minister for Health whether the 180-day reimbursement decision timeline mandated under the Health (Pricing and Supply of Medical Goods) Act 2013 was applied to the drug skyclarys (omaveloxolone); and if she will make a statement on the matter. [18771/26]
1791. Deputy Sorca Clarke asked the Minister for Health to outline the current status of the reimbursement application for skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia; if she will provide a detailed update of ongoing engagement between the HSE and the manufacturer; and the way in which the commitments contained within the National Rare Disease Strategy 2025–2030 are being applied in this case, …
1792. Deputy Sorca Clarke asked the Minister for Health the way in which the agreed timelines under the IPHA Framework Agreement 2026, including the stated 180-day decision target for reimbursement applications are being adhered to in the case of skyclarys, given that more than 570 days have elapsed since the initial application was submitted in August 2024. [18961/26]
1793. Deputy Sorca Clarke asked the Minister for Health if she will acknowledge concerns that Ireland continues to rank comparatively low in Europe for access to orphan medicines; the steps being taken to improve access rates; and if she will make a statement on the matter. [18962/26]
1818. Deputy Mairéad Farrell asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich’s ataxia during the current price negotiations for skyclarys; the way in which the commitments, which are outlined in the National Rare Disease Strategy 2025–2030, and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline), ar…
1829. Deputy Sorca Clarke asked the Minister for Health if her attention has been drawn to the supply shortages affecting atropine eye drops used in the treatment of progressive myopia in children; the steps being taken to ensure continued access to this treatment; and if she will make a statement on the matter. [19150/26]
1855. Deputy Pádraig Rice asked the Minister for Health to respond to matters raised in correspondence (details supplied); if any of the specific actions outlined can, or will, be advanced; and if she will make a statement on the matter. [19307/26]
1859. Deputy Paul Lawless asked the Minister for Health the measures in place to ensure HSE price talks for skyclarys take account for Friedreich’s ataxia time-sensitive progression. [19311/26]
1860. Deputy Paul Lawless asked the Minister for Health the way in which the National Rare Disease Strategy 2025–2030 and 2026 IPHA Framework Agreement, especially the 180-day timeline, applies to the negotiations for skyclarys; and to resolve this urgent unmet need without further postponement. [19312/26]
1886. Deputy Alan Kelly asked the Minister for Health if she will commit to make the treatment omaveloxolone available for suffers of Friedreich’s ataxia; and if she will make a statement on the matter. [19427/26]
1901. Deputy Barry Ward asked the Minister for Health further to Parliamentary Question No. 788 of 3 March 2026, the position regarding a timeline for the completion of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19446/26]
1902. Deputy Barry Ward asked the Minister for Health if any submissions can be consider as part of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19447/26]
1903. Deputy Barry Ward asked the Minister for Health if she will facilitate a meeting with the campaign group that are seeking State funded reimbursement of skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19448/26]
1904. Deputy Barry Ward asked the Minister for Health the position regarding any procedure that would allow for a meeting between the relevant Department staff and the campaign group that are seeking State funded reimbursement of skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19449/26]
1915. Deputy Keira Keogh asked the Minister for Health the position regarding the availability of Skyclarys (Omaveloxolone) for those who are living with Friedreich’s ataxia; and if she will make a statement on the matter. [19485/26]
1935. Deputy Robert Troy asked the Minister for Health the position regarding the price negotiations on the approval of Skyclarys for the treatment of Friedreich’s Ataxia; the specific steps that are being taken to ensure the HSE considers the time critical nature of Friedreich’s ataxia during the current price negotiations. [19639/26]
1936. Deputy Robert Troy asked the Minister for Health if the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA framework agreement, which aims for a 180 day decision timeline, are being applied in price negotiations for Skyclarys in the treatment of Freidreich’s ataxia. [19640/26]
1939. Deputy Seán Crowe asked the Minister for Health if a pricing and reimbursement application has been received by the HSE for zolbetuximab (Vyloy®); if the national assessment and decision process has begun; and if she will make a statement on the matter. [19668/26]
1949. Deputy Micheál Carrigy asked the Minister for Health the specific steps being taken to ensure the HSE considers the 'time-critical' nature of FA during the current price negotiations for Skyclarys; the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific case, to prevent …